Hypertriglyceridemia Clinical Trial
Official title:
The Genetic Effect on Omega 3 Fatty Acid Supplementation for the Treatment of Non Alcoholic Fatty Liver Disease in Obese Children and Adolescents
To explore whether there is a different response to omega-3 fatty acid rich diet with
respect to the hepatic fat fraction % (HFF), triglyceride, and ALT levels between the
rs738409 minor allele (GG) and the common allele homozygous (CC) of PNPLA3.
Hypothesis: We expect that subjects homozygous for the minor allele of the rs73049 SNP will
lower their triglyceride, hepatic fat content, and ALT levels more with dietary intervention
than the common allele homozygous supplementation.
Nonalcoholic fatty liver disease (NAFLD) is emerging as one of the most common complications
of childhood obesity. It is associated with and predicts the metabolic syndrome, independent
of overall obesity. Increased ALT levels are associated with deterioration in insulin
sensitivity and glucose tolerance, as well as with increasing free fatty acid (FFA) and
triglyceride levels. The prevalence of metabolic syndrome and prediabetes increases with the
increases in hepatic fat content in a cohort of obese adolescents.
Fatty liver, independent of visceral and intramyocellular lipid content plays a central role
in the impairment of liver, muscle and adipose insulin sensitivity in obese adolescents.
Thus, fatty liver disease may be the hepatic component of the metabolic syndrome.
Omega 3 fatty acids lower plasma triglyceride concentrations. The subjects entering the
omega diet study will be consuming an omega rich diet that is tailored to their caloric
needs. This calculation is based on the patient's weight, age, and gender with the purpose
of not modifying their weight at all. Weight maintenance is a very important factor in this
arm of the study. They will be on the diet for 12 weeks.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
| Completed |
NCT02250105 -
Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia
|
Phase 2 | |
| Completed |
NCT02859129 -
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
|
Phase 1 | |
| Completed |
NCT01455844 -
TRIal For Efficacy of Capre on hyperTriglyceridemiA
|
Phase 2 | |
| Completed |
NCT01437930 -
Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients
|
N/A | |
| Completed |
NCT00959842 -
Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
|
Phase 1/Phase 2 | |
| Completed |
NCT01010399 -
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
|
Phase 4 | |
| Completed |
NCT00519714 -
A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT00186537 -
Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
|
N/A | |
| Completed |
NCT00246402 -
Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
|
N/A | |
| Completed |
NCT06020950 -
Chia Seeds Consumption in Hypertriglyceridemia
|
N/A | |
| Completed |
NCT02354976 -
A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
|
Phase 2 | |
| Completed |
NCT04966494 -
Impact of Beans and Oats Snack Bar on Hypertriglyceridemic Women
|
N/A | |
| Completed |
NCT04650152 -
Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)
|
||
| Completed |
NCT04630366 -
A Phase 1, First Time in Humans Study of NST-1024
|
Phase 1 | |
| Completed |
NCT03693131 -
Efficacy of MND-2119 in Participants With Hypertriglyceridemia
|
Phase 3 | |
| Completed |
NCT04756180 -
An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.
|
Phase 3 | |
| Completed |
NCT02868177 -
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
|
Phase 2/Phase 3 | |
| Completed |
NCT01968720 -
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
|
Phase 2 | |
| Completed |
NCT01462877 -
A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic
|
Phase 4 |